Last updated: February 14, 2026
What is the Drug Identified by NDC 00187-5148?
The National Drug Code (NDC) 00187-5148 corresponds to Doxycycline Hyclate Capsules, 100 mg, a broad-spectrum tetracycline antibiotic used to treat bacterial infections including respiratory tract infections, skin infections, and sexually transmitted diseases.
The drug is FDA-approved and marketed by multiple manufacturers, primarily for outpatient use. Its patent status is expired, allowing generic manufacturing.
Market Landscape
Market Size & Usage
-
Global antibiotic market: Estimated at $50 billion in 2022, with doxycycline constituting roughly 8-10% of the volume, translating to worldwide sales of approximately $4-$5 billion.
-
United States sales: Doxycycline remains a top-prescribed antibiotic, with annual U.S. sales nearing $250 million, according to IQVIA data (2022). The U.S. accounts for roughly 25% of global prescriptions.
-
Indications: Widely used for respiratory infections, Lyme disease, chlamydia, and malaria prophylaxis.
Competitive Environment
- Generic Dominance: Multiple manufacturers produce generic doxycycline hyclate capsules, leading to high market competition and price erosion.
- Brand vs. Generic: Brand-name formulations, such as Vibramycin, typically priced 30-50% higher than generics, though market share favors generics due to cost.
Price Trends and Projections
Pricing History
- Current wholesale acquisition cost (WAC): Approximately $0.85 per capsule for 100 mg doses.
- Average retail price: Ranges from $1.20 to $1.50 per capsule, depending on pharmacy and insurance coverage.
- Pricing trends (2018-2022): Prices declined 15-20%, driven by increased competition and broader availability of generics.
Short-term (Next 1-2 Years) Price Outlook
- Price stabilization: Market saturation with generics suggests no significant price increases in the near term.
- Cost drivers: Supply chain stability, increased global manufacturing capacity, and potential policy changes impacting drug pricing.
Long-term (Next 3-5 Years) Price Outlook
- Price decline expected: As patent exclusivity ceased years ago, expect continued downward pressure.
- Emerging competition: Development of alternative antibiotics and resistance patterns could influence demand and pricing.
- Regulatory influence: Policies promoting biosimilars or alternative therapies could further impact generic prices.
Risk Factors for Price Fluctuations
- Antimicrobial resistance: Rising resistance could reduce efficacy, impacting demand.
- Supply disruptions: Raw material shortages or manufacturing issues could temporarily increase costs.
- Market entry of novel therapies: New antibiotics with better safety profiles could erode doxycycline's market share.
Regulatory and Policy Context
- No active patent protections; patents expired in the U.S. since the early 2000s.
- FDA initiatives aim to combat antimicrobial resistance, potentially influencing prescribing patterns and pricing.
- Insurance coverage and formulary decisions markedly impact actual prices paid by consumers and providers.
Summary: Market and Price Outlook
Doxycycline hyclate capsules (NDC 00187-5148) operate in a mature, highly competitive environment. Market saturation and generic prevalence characterize current conditions. Prices have declined steadily over the past 5 years and are expected to remain stable or decline slightly over the next 2-3 years, barring supply disruptions or policy shifts.
Long-term prospects hinge on resistance development and alternative therapies. Overall, doxycycline remains a low-cost, widespread antibiotic with limited pricing volatility.
Key Takeaways
- Doxycycline hyclate capsules are a widely prescribed antibiotic with significant global and U.S. market share.
- Market growth is limited due to market saturation and the dominance of generics.
- Current prices trend downward, with stability expected in the short term.
- Price declines persist due to competition and patent expiration.
- Future pricing pressures include antimicrobial resistance and potential new therapies.
FAQs
1. How does the price of NDC 00187-5148 compare with brand-name doxycycline?
Brand-name formulations like Vibramycin are priced about 30-50% higher than generics, which constitute the majority of the market.
2. Are shortages expected for doxycycline hyclate capsules?
Occasional supply disruptions have occurred historically, often due to raw material shortages or manufacturing issues, but no systemic shortages currently.
3. What factors could cause doxycycline prices to increase?
Supply chain disruptions, regulatory restrictions, or increased resistance leading to higher demand could temporarily raise prices.
4. How does resistance impact the market for doxycycline?
Rising resistance reduces drug efficacy, decreasing demand and potentially lowering prices further over time.
5. Will new antibiotics replace doxycycline in the future?
Potentially, if new therapies prove more effective with fewer side effects, but doxycycline's low cost and established safety profile sustain its continued use.
References
- IQVIA. (2022). United States Prescription Drug Market Data.
- EvaluatePharma. (2022). Global Antibiotics Market Review.
- FDA. (2021). Drug Approval and Patent Status Data.
- MarketWatch. (2022). Antibiotics Market Trends and Forecasts.
- Centers for Disease Control and Prevention. (2020). Antimicrobial Resistance Threats Report.
[1] IQVIA.
[2] EvaluatePharma.
[3] FDA.
[4] MarketWatch.
[5] CDC.
